MARKET

MRNS

MRNS

Marinus Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.840
-0.200
-6.58%
After Hours: 2.820 -0.02 -0.70% 17:59 02/21 EST
OPEN
2.780
PREV CLOSE
3.040
HIGH
2.900
LOW
2.710
VOLUME
1.53M
TURNOVER
--
52 WEEK HIGH
5.40
52 WEEK LOW
0.7700
MARKET CAP
245.58M
P/E (TTM)
-2.9107
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MRNS and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MRNS stock price target is 5.38 with a high estimate of 7.00 and a low estimate of 4.000.

EPS

MRNS News

More
  • ZS, FSLR among premarket losers
  • Seeking Alpha - Article · 1d ago
  • Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • GlobeNewswire · 02/14 21:05
  • Marinus Pharmaceuticals to Present Ganaxolone EEG Clinical Data in Status Epilepticus at the American Clinical Neurophysiology Society 2020 Annual Meeting
  • GlobeNewswire · 02/03 12:30
  • 3 Top-Notch “Strong Buy” Stocks Under $3
  • TipRanks · 01/20 09:37

Industry

Pharmaceuticals
+0.60%
Pharmaceuticals & Medical Research
+0.54%

Hot Stocks

Symbol
Price
%Change
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%
  • --
  • 0.00%

About MRNS

Marinus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders. Its clinical-stage product candidate, ganaxolone, is a modulator being developed in various dose forms, including intravenous, oral capsule and oral liquid, intended to provide more treatment options to adult and pediatric patient populations in both acute and chronic care settings. Ganaxolone acts on the GABAA receptor, a target in the brain known for both anti seizure and anti anxiety effects through positive allosteric modulation. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19 pediatric epilepsy.
More

Webull offers kinds of Marinus Pharmaceuticals Inc stock information, including NASDAQ:MRNS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRNS stock news, and many more online research tools to help you make informed decisions.